USE OF GENETIC POLYMORPHISMS THAT ASSOCIATE WITH EFFICACY OF TREATMENT OF INFLAMMATORY DISEASE
The MHC III region of chromosome 6p21.3 harbors a DNA sequence, most likely within the TNF or LTA gene, which influences response to pimecrolimus for the treatment of atopic dermatitis. Accordingly, genetic polymorphisms in the TNF andLTA genes are useful as biomarkers of the efficacy of pimecrolimu...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | eng ; spa |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The MHC III region of chromosome 6p21.3 harbors a DNA sequence, most likely within the TNF or LTA gene, which influences response to pimecrolimus for the treatment of atopic dermatitis. Accordingly, genetic polymorphisms in the TNF andLTA genes are useful as biomarkers of the efficacy of pimecrolimus treatment of inflammatory disease. By contrast, response to tacrolimus appears to be influenced by other biological pathways.
La region MHC III del cromosoma 6p21.3 aloja a una secuencia de ADN, mas posiblemente dentro del gen TNF o LTA, que tiene influencia sobre la respuesta al pimecrolimus para el tratamiento de dermatitis atopica. De acuerdo con lo anterior, los polimorfismos geneticos en los genes TNF y LTA son utiles como biomarcadores de la eficacia del tratamiento con pimecrolimus de la enfermedad inflamatoria. En contraste, la respuesta al tacrolimus parece ser influenciada por otras sendas biologicas. |
---|